| Literature DB >> 31381578 |
Laila Darwich1,2, Anna Vidal1, Chiara Seminati1, Andreu Albamonte1, Alba Casado1, Ferrán López1, Rafael A Molina-López3, Lourdes Migura-Garcia2.
Abstract
Most of the studies focused on antimicrobial resistance (AMR) performed in wildlife describe Escherichia coli as the principal indicator of the selective pressure. In the present study, several species of Enterobacterales with a large panel of cephalosporin resistant (CR) genes have been isolated from wildlife in Catalonia. A total of 307 wild animals were examined to determine the prevalence of CR enterobacteria, AMR phenotypes and the presence of common carbapenem and CR genes. The overall prevalence of CR-phenotype was 13% (40/307): 17.3% in wild mammals (18/104) and 11.5% in wild birds (22/191) (p<0.01). Hedgehogs showed the highest prevalence (13.5% of 104) of the mammal specimens, and raptors the highest in bird specimen (7.3% of 191). Although CR E. coli was the most frequently isolated (45%), other CR- Enterobacterales like Klebsiella pneumoniae (20%), Citrobacter freundii (15%), Enterobacter cloacae (5%), Proteus mirabilis (5%), Providencia spp (5%) and Serratia marcescens (2.5%) were also isolated. A high diversity of CR genes was identified among the isolates, with 50% yielding blaCMY-2, 23% blaSHV-12, 20% blaCMY-1 and 18% blaCTX-M-15. Additionally, resistance to carbapenems associated to OXA-48 gene was found. Most of the CR isolates, principally K. pneumoniae and C. freundii, were multi-resistant with co-resistance to fluoroquinolones, tetracycline, sulphonamides and aminoglycosides. This study reports high prevalence of Enterobacterales harbouring a variety of CR genes and OXA-48 mediated-carbapenem resistance, all of them frequently associated to nosocomial human infections, for the first time in wild mammals and wild birds. Implementation of control measures to reduce the impact of anthropogenic pressure in the environment is urgently needed.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31381578 PMCID: PMC6681944 DOI: 10.1371/journal.pone.0210686
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Proportion of wildlife analysed in the study according to the zoological category.
Animal groups: raptors (different species of birds of prey and owls), wild birds (principally passerines and seagulls), insectivorous (European and Algerian hedgehogs), carnivores (mainly mustelids), and other mammals (wild boars and roe deer).
Fig 2Prevalence of cephalosporin resistant (CR) bacteria in the different wildlife categories.
Fig 3Venn diagram showing the distribution of AMR genes in the different animal groups encountered in this study.
Prevalence and antimicrobial resistance genotypes and phenotypes of beta-lactamase producing Enterobacterales detected in wildlife.
| Total sample | AMR genes | Bacterial spp | Drug-resistance genes | Resistance phenotype to | ||
|---|---|---|---|---|---|---|
| 3 | 2 | 67% | CMY-2 | CIP, NAL, KAN, TMP | ||
| CTX-M-3 | GEN, ST, FF, CF, TET, COL, TMP | |||||
| 47 | 12 | 26% | CMY-2 | nd | ||
| CMY-2 | KAN | |||||
| CMY-2 | nd | |||||
| SHV-12 | STR | |||||
| SHV-11,OXA-48 | CIP, NAL, KAN, TET, SUL, TMP | |||||
| CMY-1,CMY-2, SHV-1,TEM-1,CTX-M-15 | CIP, GEN, ST, KAN, TET, SUL, TMP | |||||
| SHV-11, TEM-1 | CIP, NAL, GEN, STP, KAN, TET, SUL, TMP | |||||
| SHV-28 | CIP, NAL, GEN, STR, KAN, TET, COL, SUL, TMP | |||||
| SHV-12 | CIP, NAL, KAN, TET, SUL, TMP | |||||
| CMY-2, TEM-1 | CIP, NAL, KAN, TET, TMP | |||||
| CMY-2, SHV-12 | CIP, NAL, STR, KAN, TET, COL, SUL, TMP | |||||
| CMY-2 | CIP, NAL | |||||
| 2 | 1 | na | CMY-2 | SUL | ||
| 2 | 1 | na | CMY-2, SHV-12 | CIP, NAL, GEN, TET, SUL, TMP | ||
| 1 | 1 | na | SHV-12 | CIP, NAL, CHL, SUL, TMP | ||
| 13 | 1 | 8% | CMY-2 | SUL | ||
| 13 | 3 | 23% | TEM-1 | COL | ||
| CMY-2 | CIP, NAL | |||||
| CMY-1, CMY-2, SHV-28, TEM-1 | CIP, NAL, GEN, STR, KAN, TET, SUL, TMP | |||||
| 8 | 3 | 38% | CMY-1, SHV-1, TEM-1, CTX-M-15 | CIP, NAL, KAN, TET, SUL, TMP | ||
| TEM-1 | CIP, TET, TMP | |||||
| CMY-1, CTX-M-15 | CIP, TET, COL, SUL, TMP | |||||
| 1 | 1 | na | CMY-1, SHV-167 | nd | ||
| 17 | 2 | 12% | SHV-12 | ST, CHL, TET, SUL, TMP | ||
| SHV-12 | CIP, NAL,GEN,ST,KAN, FF,CHL, TET,SUL, TMP | |||||
| 18 | 3 | 17% | CMY-2, SHV-28 | STR, SUL, TMP | ||
| CMY-2, SHV-1 | nd | |||||
| SHV-12, CTX-M15 | CIP | |||||
| 3 | 2 | 67% | CMY-2 | CIP, NAL, STR, TET | ||
| SHV-12,TEM-1, OXA-48 | CIP, NAL, STR, KAN, CF, TET, COL, SUL,TMP | |||||
| 12 | 1 | 8% | CMY-2 | CIP, NAL, GEN, STR, KAN, CHL, TET, SUL, TMP | ||
| 2 | 1 | na | CMY-1 | CIP, NAL, KAN, FF, CHL, SUL | ||
| 7 | 1 | 14% | CTX-M-15 | CIP, NAL, GEN, KAN, TET, SUL, TMP | ||
| 6 | 1 | 17% | CMY-1, SHV-28 | CIP, NAL, STR, KAN, TET, SUL, TMP | ||
| 1 | 1 | na | CMY-2 | FF, TMP | ||
| 6 | 2 | 33% | CMY-2 | CIP, NAL | ||
| CTX-M-15, CMY-1 | CIP, NAL, GEN, STR, KAN, CHL, TET, SUL, TMP | |||||
| 8 | 1 | 13% | CMY-2 | CIP, NAL, KAN, TMP | ||
CIP, Ciprofloxacin; NAL, Nalidixic acid; GEN, Gentamicin; STR, Streptomycin; KAN, Kanamycin; FF, Florfenicol; CHL, Chloramphenicol; TET, Tetracycline; COL, Colistin; SUL, Sulphametoxazole; TMP, Trimethoprim. nd, not detected.
Minimal inhibitory concentration of E. coli, K. pneumoniae and C. freundii isolates of wildlife origin.
Dilution ranges for each antimicrobial are those contained within the white area. Vertical lines indicate epidemiological cut off values (ECOFF) or clinical breakpoints in those cases where ECOFF values have not been described.
| MIC [μg/mL]: | 0.12 | 0.25 | 0.5 | 1 | >2 | 4 | 8 | 16 | >16 | 32 | 64 | >128 | 256 | >512 | R (%) |
| Ampicilin | 3 | 15 | 100 | ||||||||||||
| Cefotaxime | 1 | 1 | 1 | 2 | 12 | 1 | 89 | ||||||||
| Ceftazidime | 2 | 1 | 1 | 7 | 7 | 100 | |||||||||
| Ciprofloxacin | 6 | 2 | 2 | 8 | 67 | ||||||||||
| Nalidixic acid | 2 | 3 | 4 | 9 | 50 | ||||||||||
| Gentamicin | 9 | 8 | 1 | 5.5 | |||||||||||
| Streptomycin | 7 | 3 | 5 | 2 | 1 | 17 | |||||||||
| Kanamycin | 12 | 2 | 4 | 33 | |||||||||||
| Florfenicol | 4 | 12 | 2 | 0 | |||||||||||
| Chloramphenicol | 2 | 8 | 5 | 1 | 2 | 11 | |||||||||
| Tetracycline | 6 | 6 | 1 | 2 | 3 | 33 | |||||||||
| Colistin | 17 | 1 | 5.5 | ||||||||||||
| Sulphametoxazole | 2 | 9 | 1 | 1 | 5 | 28 | |||||||||
| Trimethoprim | 1 | 7 | 2 | 8 | 44 | ||||||||||
| MIC [μg/mL]: | 0.12 | 0.25 | 0.5 | 1 | >2 | 4 | 8 | 16 | >16 | 32 | 64 | >128 | 256 | >512 | R (%) |
| Ampicilin | 1 | 8 | 100 | ||||||||||||
| Cefotaxime | 9 | 100 | |||||||||||||
| Ceftazidime | 3 | 6 | 100 | ||||||||||||
| Ciprofloxacin | 1 | 8 | 100 | ||||||||||||
| Nalidixic acid | 1 | 2 | 1 | 5 | 88 | ||||||||||
| Gentamicin | 1 | 5 | 3 | 33 | |||||||||||
| Streptomycin | 2 | 2 | 2 | 3 | ND | ||||||||||
| Kanamycin | 2 | 7 | 78 | ||||||||||||
| Florfenicol | 1 | 7 | 1 | ND | |||||||||||
| Chloramphenicol | 1 | 5 | 1 | 1 | 1 | 22 | |||||||||
| Tetracycline | 1 | 1 | 2 | 1 | 4 | 56 | |||||||||
| Colistin | 8 | 1 | 11 | ||||||||||||
| Sulphametoxazole | 1 | 8 | 89 | ||||||||||||
| Trimethoprim | 1 | 2 | 6 | 67 | |||||||||||
| MIC [μg/mL]: | 0.12 | 0.25 | 0.5 | 1 | >2 | 4 | 8 | 16 | >16 | 32 | 64 | >128 | 256 | >512 | R (%) |
| Ampicilin | 1 | 5 | 100 | ||||||||||||
| Cefotaxime | 1 | 5 | 83 | ||||||||||||
| Ceftazidime | 1 | 1 | 4 | 83 | |||||||||||
| Ciprofloxacin | 1 | 5 | 0 | ||||||||||||
| Nalidixic acid | 1 | 5 | 83 | ||||||||||||
| Gentamicin | 1 | 1 | 2 | 2 | 33 | ||||||||||
| Streptomycin | 1 | 1 | 2 | 1 | 1 | ND | |||||||||
| Kanamycin | 3 | 3 | 50 | ||||||||||||
| Florfenicol | 3 | 2 | 1 | ND | |||||||||||
| Chloramphenicol | 1 | 2 | 1 | 1 | 1 | 33 | |||||||||
| Tetracycline | 2 | 1 | 2 | 1 | 67 | ||||||||||
| Colistin | 4 | 1 | 1 | 33 | |||||||||||
| Sulphametoxazole | 2 | 1 | 3 | 50 | |||||||||||
| Trimethoprim | 1 | 5 | 83 | ||||||||||||
EUCAST (ECOFF values WT): AMP ≤8, CTX ≤0.25, CAZ ≤0.5 (≤1 C.freundii), CIP ≤0.064 (≤0.125 K.pneumoniae), NAL ≤16, GEN ≤2, STR≤ 16, KAN ≤8, FFL ≤16, CHL ≤16, TET ≤8, COL ≤2, SMX ≤64, TMP ≤2 (≤8 K. pneumoniae and C. freundii).
aBSAC and
bCLSI clinical break points: CIP ≤1 Enterobacteriaceae, SMX Susceptible ≤256 K. pneumoniae and C. freundii; TMP ≤8 K. pneumoniae and C. freundii. ND, not determined due to lack of ECOFF or clinical breakpoint values available. CLSI: Performance Standards for Antimicrobial Susceptibility Testing. 27th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.